ライフサイエンスコーパス: dimeglumine

1 er-17 and r = 0.80, P <.05 for gadopentetate dimeglumine).

2 r-17 and r = 0.75, P <.001 for gadopentetate dimeglumine).

3 te dimeglumine), and 1.91 nmol/g (gadobenate dimeglumine).

4 the kinetics of di-tyrosine of gadopentetate dimeglumine.

5 ng intravenous administration of gadopentate dimeglumine.

6 ynamic injection of 8-10 mL of gadopentetate dimeglumine.

7 and mean transit time (MTT) of gadopentetate dimeglumine.

8 intravenous bolus injection of gadopentetate dimeglumine.

9 red with that with 0.1 mmol/kg gadopentetate dimeglumine.

10 ntetate dimeglumine and 0.5 mol/L gadobenate dimeglumine.

11 before and after injection of gadopentetate dimeglumine.

12 dose (2 mL or 0.01 mmol/kg) of gadopentetate dimeglumine.

13 mote myocardium than that with gadopentetate dimeglumine.

14 ter a 30-40-minute infusion of gadopentetate dimeglumine.

15 nd after the administration of gadopentetate dimeglumine.

16 before and after injection of gadopentetate dimeglumine.

17 re obtained after injection of gadopentatate dimeglumine.

18 intravenous administration of gadopentetate dimeglumine.

19 istration of a single bolus of gadopentetate dimeglumine.

20 e and during administration of gadopentetate dimeglumine.

21 administration of 0.2 mmol/kg gadopentetate dimeglumine.

22 administration of 0.2 mmol/kg gadopentetate dimeglumine.

23 on of a 0.5-mL timing bolus of gadopentetate dimeglumine.

24 doses of 0.075 and 0.1 mmol/kg gadopentetate dimeglumine.

25 re and after administration of gadopentetate dimeglumine.

26 during infusion of 0.2 mmol/kg gadopentetate dimeglumine.

27 hases with saline and 2 mmol/L gadopentetate dimeglumine.

28 ht joints), after injection of gadopentetate dimeglumine.

29 administration of 0.1 mmol/kg gadopentetate dimeglumine.

30 e disodium and 204 performed with gadobenate dimeglumine.

31 imeglumine was substituted for gadopentetate dimeglumine.

32 al baseline reaction rate with gadopentetate dimeglumine.

33 lergic-like reactions than was gadopentetate dimeglumine.

34 more often than with intravenous gadobenate dimeglumine.

35 material-enhanced imaging with gadopentetate dimeglumine.

36 a dual-bolus administration of gadopentetate dimeglumine (0.0025 mmol/kg followed by 0.10 mmol/kg).

37 intravenous administration of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevi

38 intravenous administration of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevi

39 intravenous administration of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevi

40 intravenous administration of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevi

41 re and after administration of gadopentetate dimeglumine (0.1 mmol per kilogram of body weight).

42 n = 1; 16 mL, n = 1] and 99 with gadobenate dimeglumine [0.1 mmol per kilogram of body weight, maxim

43 fic (di-5-hydroxytryptamide of gadopentetate dimeglumine, 0.1 mmol per kilogram of bodyweight) or a n

44 n-MPO-specific (di-tyrosine of gadopentetate dimeglumine, 0.1 mmol/kg) contrast agent, animals underw

45 re randomized to 1 of 3 doses of gadopentate dimeglumine: 0.05, 0.10, or 0.15 mmol/kg.

46 All animals received gadopentetate dimeglumine 1 hour after reperfusion and underwent imagi

47 ith gadoxetate disodium than with gadobenate dimeglumine (10.7% [37 of 345 examinations] vs 0.5% [one

48 tate disodium administration than gadobenate dimeglumine (14% [14 of 99] vs 5% [five of 99], P = .05)

49 ium, 16.6 mL vs 16.6 mL, P = .99; gadobenate dimeglumine, 18.0 mL vs 17.8 mL, P = .77) and mean time

50 dolinium-based contrast media (gadopentetate dimeglumine, 31 540; gadobenate dimeglumine, 66 152; oth

51 on-related artifact compared with gadobenate dimeglumine (39% vs 10%, P < .0001) and of new severe tr

52 adopentetate dimeglumine, 31 540; gadobenate dimeglumine, 66 152; other, 7915).

53 amide, gadopentetate dimeglumine, gadobenate dimeglumine), a macrocyclic GBCA (gadobutrol, gadoterate

54 ients receiving multiple doses of gadobenate dimeglumine, a linear relationship existed between gadob

55 imeglumine was substituted for gadopentetate dimeglumine, a significant transient increase occurred i

56 mmol per kilogram of body weight gadobenate dimeglumine administered at a rate of 2.0 mL per second)

57 different IRE parameters after gadopentetate dimeglumine administration.

58 F) MR imaging before and after gadopentetate dimeglumine administration.

59 tive patients before and after gadopentetate dimeglumine administration.

60 nt are affected by the rate of gadopentetate dimeglumine administration.

61 near relationship existed between gadobenate dimeglumine administrations and an increase in the denta

62 change at MRI following multiple gadobenate dimeglumine administrations.

63 loped NSF after administration of gadobenate dimeglumine after more than 2 years' mean follow-up.

64 Liposomes encapsulating gadopentetate dimeglumine, an MR-detectable model representing pharmac

65 myocardium (0.23 +/- 0.02 for gadopentetate dimeglumine and 0.16 +/- 0.01 for 99mTc-DTPA).

66 am of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine.

67 myocardium (0.90 +/- 0.05 for gadopentetate dimeglumine and 0.89 +/- 0.04 for 99mTc-DTPA) than in no

68 tional distribution volumes of gadopentetate dimeglumine and 99mTc-DTPA are similar and indicate extr

69 o 10, 30, and 50 minutes after gadopentetate dimeglumine and both gadomer-17 injections, respectively

70 ning rat was administered both gadopentetate dimeglumine and cationized ferritin to visualize the int

71 Gadobenate dimeglumine and gadopentetate dimeglumine were the agent

72 ng the switch from gadodiamide to gadobenate dimeglumine and gadopentetate dimeglumine, and the adopt

73 istration of mesoporphyrin and gadopentetate dimeglumine and histochemical staining, the function and

74 eline in NASH mice imaged with gadopentetate dimeglumine and in MPO knockout NASH mice with MPO-Gd, w

75 ed intraarticular injection of gadopentetate dimeglumine and normal saline in a ratio of 1:200.

76 nce of 3.1 msec was noted between gadobenate dimeglumine and placebo (95% CI: -1.8, 8.0) after indivi

77 Gadobenate dimeglumine and saline placebo were injected intravenous

78 he relationship between dosage of gadobenate dimeglumine and SI change at MRI following multiple gado

79 lationship between the dose of gadopentetate dimeglumine and the time to onset of NSF.

80 fact was threefold dilution of gadopentetate dimeglumine and use of a short echo time (1 msec).

81 er-17 and r = 0.60, P =.05 for gadopentetate dimeglumine) and with areas of reduced MBF (r = 0.70, P

82 /g (gadodiamide), 2.13 nmol/g (gadopentetate dimeglumine), and 1.91 nmol/g (gadobenate dimeglumine).

83 oved Gd chelate, Multihance((R)) (gadobenate dimeglumine), and a novel experimental liposomal Gd agen

84 (gadodiamide, gadoversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine) produced a maxi

85 gents (gadopentetate dimeglumine, gadobenate dimeglumine, and gadofosveset trisodium) diluted in eith

86 ur GBCAs gadodiamide, gadobutrol, gadobenate dimeglumine, and gadoterate meglumine, and to determine

87 ree or more MRI examinations with gadobenate dimeglumine, and had the baseline scan and another brain

88 general enhancement seen with gadopentetate dimeglumine, and reflux from the duodenum could not acco

89 to gadobenate dimeglumine and gadopentetate dimeglumine, and the adoption of restrictive GBCA polici

90 intravenous administration of gadopentetate dimeglumine, and these data were used to calculate EF.

91 ths after exposure), including gadopentetate dimeglumine, and two GBCA-naive donors were also evaluat

92 rs, the other 16 rats received gadopentetate dimeglumine at 24 hours, and all animals underwent imagi

93 Therefore, half-dose gadobenate dimeglumine at 3-T MR imaging may be sufficient for asse

94 dimeglumine, gadodiamide, and gadopentetate dimeglumine at a concentration of 0.1 mmol/L and by gado

95 ed after the administration of gadopentetate dimeglumine at a concentration of 25% with fast SPGR (6/

96 glumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after inje

97 (P <.05) higher than that with gadopentetate dimeglumine at first-pass imaging.

98 terate meglumine, gadobutrol, and gadobenate dimeglumine) at 0.1 mmol/kg.

99 tients after administration of gadopentetate dimeglumine (average dose, 0.11 mmol/kg).

100 application of the linear GBCA gadopentetate dimeglumine but not by the macrocyclic GBCA gadoterate m

101 administration of 0.1 mmol/kg gadopentetate dimeglumine by means of bolus (10-second) injection (n =

102 form a commercial Gd-based agent (gadobenate dimeglumine) by more than eight-fold at physiological te

103 was filled with a solution of gadopentetate dimeglumine, catheter movement was always depicted.

104 nd vasculitis mice imaged with gadopentetate dimeglumine (CNR = 10.6) (P < .05).

105 ificantly worse than those in the gadobenate dimeglumine cohort (P < .005).

106 (P <.05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglu

107 ors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopent

108 the linear agents gadodiamide and gadobenate dimeglumine compared with the macrocyclic agents gadobut

109 normalized to pectoral muscle gadopentetate dimeglumine concentration in invasive cancers was also c

110 The T1 values, change in gadopentetate dimeglumine concentration, and extraction-flow products

111 atients with prior exposure to gadopentetate dimeglumine contrast during imaging studies.

112 Gadopentetate dimeglumine did not produce selective enhancement of the

113 yed by using mesoporphyrin and gadopentetate dimeglumine differed from each other.

114 Gadopentetate dimeglumine diluted 1:1 with 0.9% normal saline was used

115 Gadobenate dimeglumine dose was weight based (0.1 mmol per kilogram

116 ed higher cumulative and total gadopentetate dimeglumine doses had a higher risk of developing NSF th

117 se (approximately 0.1 mmol/kg) gadopentetate dimeglumine during a three-station, dual-injection exami

118 Hyperintensity from gadopentetate dimeglumine enabled visualization of renal tubules, and

119 TOF sequences with or without gadopentetate dimeglumine enables accurate identification of the proxi

120 Ninety patients underwent gadobenate dimeglumine-enhanced abdominal magnetic resonance (MR) f

121 44,224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations.

122 2 included patients who underwent gadobenate dimeglumine-enhanced MR imaging.

123 -saturated T1-weighted dynamic gadopentetate dimeglumine-enhanced sequences also were performed.

124 ide-enhanced studies but not with gadobenate dimeglumine-enhanced studies, likely reflecting differen

125 d between half-dose and full-dose gadobenate dimeglumine-enhanced synovial tissue (mean: 914.35 +/- 2

126 sms, di-5-hydroxytryptamide of gadopentetate dimeglumine exhibited delayed washout kinetics compared

127 within 3 months after the last gadopentetate dimeglumine exposure (range, 1-59 months) in 21 (66%) of

128 Conclusion Repeated gadopentetate dimeglumine exposure is associated with gadolinium reten

129 records were then reviewed for gadopentetate dimeglumine exposure, renal status, concomitant diseases

130 d pre- and postcontrast (20 mL gadopentetate dimeglumine) fat-saturated 2D GRE breath-hold imaging an

131 d well with those observed for gadopentetate dimeglumine (Fe-tCDTA Pearson R, 0.99; P = .0003; Fe-DTP

132 veric knees, with placement of gadopentetate dimeglumine-filled tubes along their course and tibial i

133 ed to receive either MPO-Gd or gadopentetate dimeglumine first.

134 for gadoxetate disodium than for gadobenate dimeglumine for both the general population (17% [17 of

135 tent CNR improvements than did gadopentetate dimeglumine; further evaluation of its utility for coron

136 ed a linear GBCA (gadodiamide, gadopentetate dimeglumine, gadobenate dimeglumine), a macrocyclic GBCA

137 ee gadolinium contrast agents (gadopentetate dimeglumine, gadobenate dimeglumine, and gadofosveset tr

138 as stimulated by gadoversetamide, gadobenate dimeglumine, gadodiamide, and gadopentetate dimeglumine

139 dolinium-based contrast agent, gadopentetate dimeglumine (Gd(DTPA)(2-)), was used as the imageable ca

140 iaminetriacetate (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the excretion, pha

141 The use of gadopentetate dimeglumine (Gd-DTPA) as a contrast agent showed smaller

142 Gadopentetate dimeglumine (Gd-DTPA) dynamic magnetic resonance imaging

143 ration of the MRI contrast agent gadopentate dimeglumine [Gd-DTPA(2-)]) is used as an index of the mo

144 rformed with 5 mL of undiluted gadopentetate dimeglumine hand injected into each renal artery (total

145 Injection of 0.2 mmol/kg gadobenate dimeglumine has no detrimental effect on cardiac electro

146 Published data on gadobenate dimeglumine have been somewhat contradictory.

147 atively large cumulative doses of gadoterate dimeglumine, healthy women at high risk for breast cance

148 The use of gadopentetate dimeglumine improved delineation of soft-tissue inflamma

149 intrathecal administration of gadopentetate dimeglumine in 15 patients clinically suspected of havin

150 maging and/or MR angiography with gabobenate dimeglumine in 2010.

151 l impairment after exposure to gadopentetate dimeglumine in a dose- and time-dependent manner.

152 amide and one had been exposed to gadobenate dimeglumine in addition to gadodiamide.

153 es were compared with those of gadopentetate dimeglumine in blood serum phantoms at 1.5 T, 3 T, and 7

154 Normal-saline bags containing gadopentetate dimeglumine in concentrations of 0-20 mmol/L were imaged

155 uired during the first pass of gadopentetate dimeglumine in coronary arteries and up to 6 and 10 minu

156 es of abdominal MRI with low-dose gadobenate dimeglumine in liver transplant recipients at a single c

157 gnificantly more often than after gadobenate dimeglumine in patients who received both contrast media

158 ficantly longer than those for gadopentetate dimeglumine in regions of postinfarction scarring (mean,

159 the application of 0.2 mmol/kg gadopentetate dimeglumine in the interventricular septum, left ventric

160 igher for gadoteridol than for gadopentetate dimeglumine in the physis, epiphyseal cartilage, and sec

161 Inclusion of phantoms of gadopentetate dimeglumine in tubes allowed estimation of intravascular

162 m of tissue (95% CI: 3.5, 6.1) in gadobenate dimeglumine-injected rats, and 6.9 mug gadolinium per gr

163 minimally efficacious dose of gadopentetate dimeglumine injection (Magnevist Injection; Berlex Labor

164 seven of 47 (15%) subjects after gadobenate dimeglumine injection and in five of 47 (11%) subjects a

165 ent IRE ablation without prior gadopentetate dimeglumine injection to serve as control animals.

166 lse sequences before and after gadopentetate dimeglumine injection.

167 t on the images obtained after gadopentetate dimeglumine injection.

168 nsional gradient-echo MR after gadopentetate dimeglumine injection.

169 ts (nine who had received GBCA gadopentetate dimeglumine injections previously [one to eight times] a

170 onic contrast agent; n = 6) or gadopentetate dimeglumine (ionic contrast agent; n = 6).

171 baseline renal function, MRI with gadobenate dimeglumine is a nonnephrotoxic imaging modality in live

172 Gadopentetate dimeglumine is an alternative radiographic contrast mate

173 A low dose of 0.05 mmol/kg gadopentetate dimeglumine is at least as efficacious as higher doses.

174 y with intranodal injection of gadopentetate dimeglumine is feasible, produces good images of the cen

175 Gadopentetate dimeglumine is of limited use.

176 contrast-enhancing lesions on gadopentetate dimeglumine magnetic resonance images after treatment wi

177 the 2nd year after it replaced gadopentetate dimeglumine (maximum per quarter, 0.10% [four of 4122];

178 Gadobenate dimeglumine may be safe in this population.

179 emarcated by mesoporphyrin and gadopentetate dimeglumine may provide an estimation of potentially sal

180 on imaging with Gadomer-17 and gadopentetate dimeglumine, microsphere blood flow (MBF) testing, and t

181 ected contrast agent solution (gadopentetate dimeglumine mixed with trypan blue dye) in and around th

182 traarticular administration of gadopentetate dimeglumine (MR arthrography).

183 mide (n = 6), gadobutrol (n = 1), gadobenate dimeglumine (n = 1), multiple (n = 41), and unknown (n =

184 23), referred to as MPO-Gd, or gadopentetate dimeglumine (n = 10).

185 cluding gadodiamide (n = 307), gadopentetate dimeglumine (n = 49), gadoversetamide (n = 6), gadobutro

186 nd verified qualitatively with gadopentetate dimeglumine on both perfusion and BOLD images obtained a

187 maging in the same tumors with gadopentetate dimeglumine on day 2.

188 ntravenous injection of either gadopentetate dimeglumine or EP-3533.

189 intravenous bolus injection of gadopentetate dimeglumine or gadoteridol (0.1 mmol/kg), nine images we

190 e use of either a linear GBCA (gadopentetate dimeglumine) or a macrocyclic GBCA (gadoterate meglumine

191 e), linear GBCAs (gadodiamide and gadobenate dimeglumine), or saline.

192 administration of 134 mL +/- 141 gadobenate dimeglumine over 55 months +/- 35.2.

193 gnificant (P <.05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted bot

194 The reaction rate for gadobenate dimeglumine peaked (maximum per quarter, 0.38% [16 of 42

195 three injections: 0.20 mmol of gadopentetate dimeglumine per kilogram of body weight and 0.05 and 0.1

196 ed after injection of 0.1 mmol gadopentetate dimeglumine per kilogram of body weight.

197 tion of a bolus of 0.1 mmol of gadopentetate dimeglumine per kilogram of body weight.

198 administration of 0.2 mmol of gadopentetate dimeglumine per kilogram of body weight.

199 Gadobenate dimeglumine phantoms with a wide range of T1 values were

200 -specific GBCAs, Gd-EOB-DTPA, and gadobenate dimeglumine, primarily though OATP transporters.

201 -83 years) had been exposed to gadopentetate dimeglumine prior to NSF onset.

202 e, gadopentetate dimeglumine, and gadobenate dimeglumine) produced a maximum stimulation of fibroblas

203 Extracellular gadopentetate dimeglumine provided excellent infarct detection but a s

204 55 seconds after injection of gadopentetate dimeglumine (PSIC, 36% +/- 24 vs 56% +/- 27, respectivel

205 32, respectively; P <.001) and gadopentetate dimeglumine (PSIC, 49% +/- 31 vs 81% +/- 43, respectivel

206 e of 0.015% +/- 0.004 per 1 mL of gadobenate dimeglumine (R(2) = 0.3, P < .001).

207 tively, compared with those of gadopentetate dimeglumine (r1 = 4.1 mmol(-1) .

208 The final gadobenate dimeglumine reaction rate (last 3 quarters, 0.12% [17 of

209 isibility of the physis, while gadopentetate dimeglumine resulted in greater contrast between the phy

210 with di-5-hydroxytryptamide of gadopentetate dimeglumine revealed a difference in enhancement ratio b

211 ed intraarticular injection of gadopentetate dimeglumine, ropivacaine 0.5%, and normal saline in a ra

212 ilable catheters filled with a gadopentetate dimeglumine solution and a fast, two-dimensional, time-r

213 patients by using a first-pass gadopentetate dimeglumine T2*-weighted echo-planar perfusion sequence

214 rague-Dawley rats treated with gadopentetate dimeglumine (three doses over 4 weeks; cumulative gadoli

215 se rats, two were administered gadopentetate dimeglumine to visualize renal tubules on T1-weighted gr

216 Results Gadopentetate dimeglumine-treated rats showed region-, subregion-, and

217 ise quantitative estimation of gadopentetate dimeglumine uptake in breast tumors, which helps improve

218 olinium deposition in the DN with gadobenate dimeglumine use, although it is considerably less than t

219 n exposed to median cumulative gadopentetate dimeglumine volumes of 35, 40, 85, and 117.5 mL over the

220 nal artery stenosis, undiluted gadopentetate dimeglumine was administered in an aortic bolus to provi

221 Gadobenate dimeglumine was associated with significantly more overa

222 Renal extraction fraction of gadopentetate dimeglumine was determined with T1 measurements of flowi

223 hic attenuation of the diluted gadopentetate dimeglumine was equivalent to diatrizoate meglumine dilu

224 n the timing examination, 1 mL gadopentetate dimeglumine was followed with 15 mL saline, both at 2 mL

225 re, a single dose of 0.5 mL of gadopentetate dimeglumine was injected into the lumbar subarachnoid sp

226 For comparison, gadopentetate dimeglumine was injected into three other swine at a dos

227 or gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the

228 Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site in

229 quence after administration of gadopentetate dimeglumine was obtained.

230 traarticular administration of gadopentetate dimeglumine was performed in 10 adult cadaveric glenohum

231 Gadopentetate dimeglumine was peripherally injected at rest and during

232 site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; ga

233 ed in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patien

234 years before and 3.5 years after gadobenate dimeglumine was substituted for gadopentetate dimeglumin

235 After gadobenate dimeglumine was substituted for gadopentetate dimeglumin

236 graphy performed with 30 mL of gadopentetate dimeglumine was the reference standard.

237 ory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C

238 than at the two centers where gadopentetate dimeglumine was used.

239 lysis was performed to assess the gadobenate dimeglumine washout since the last gadolinium exposure.

240 l injections of small doses of gadopentetate dimeglumine were combined with a fast spoiled-gradient-e

241 sed contrast agents other than gadopentetate dimeglumine were excluded.

242 te after the administration of gadopentetate dimeglumine were retrospectively evaluated for perilesio

243 Gadobenate dimeglumine and gadopentetate dimeglumine were the agents used in the postadoption per

244 who underwent MR imaging with gadopentetate dimeglumine) were identified.

245 gent di-5-hydroxytryptamide of gadopentetate dimeglumine, which is a paramagnetic MPO substrate that

246 travenous injection of 2 mL of gadopentetate dimeglumine, which was repeated following intravenous in

247 ol per kilogram of body weight of gadobenate dimeglumine, with 19 patients receiving contrast materia

248 eased linearly with the amount of gadobenate dimeglumine, with a mean increase of 0.015% +/- 0.004 pe

249 ically after administration of gadopentetate dimeglumine, with the first enhanced acquisition timed f